Purpose {#S0001}
=======

Multiple treatment options are available for clinically localized prostate cancer, including radical prostatectomy, external beam radiotherapy (EBRT), brachytherapy, and a combination of EBRT and brachytherapy. Brachytherapy in the form of a permanent low-dose-rate (LDR) seed implant, or as high-dose-rate (HDR) afterloading, can deliver a highly localized radiation dose to the tumor. While LDR brachytherapy has been examined and assessed the most, and become a standard treatment option, HDR brachytherapy has recently gained momentum as an alternative. Several features of HDR brachytherapy, including uniformly accurate, precise, and reproducible dosimetry resulting from its advanced optimization capabilities, radiobiological and radioprotective advantages, as well as reduced costs, have made HDR attractive for the treatment of prostate cancer. These advantages avoid the dosimetric uncertainties of LDR related to post implant volume changes, due to needle trauma and subsequent edema during the overall treatment period of several months. High-dose-rate significantly improves the radiation dose distribution, because it can modulate and accurately control both the spatial source position and dwell time during treatment \[[@CIT0001]\].

Historically, HDR brachytherapy was introduced to boost EBRT \[[@CIT0002], [@CIT0003]\]. However, this combination typically adds 4-5 weeks to the time needed for completion of EBRT, in addition to hospitalization for HDR brachytherapy \[[@CIT0004]\]. High-dose-rate brachytherapy as monotherapy, on the other hand, would definitely be the most efficient method of achieving a high degree of conformity and dose escalation. Our group was the first to report on the use of HDR brachytherapy as monotherapy \[[@CIT0005]\], and subsequently reported its promising preliminary and interim outcomes \[[@CIT0006]--[@CIT0009]\]. However, to date there are only a small number of centers worldwide that carry out HDR monotherapy. Because HDR monotherapy does not include supplemental EBRT, it requires technical maturity in terms of both implant technique and treatment planning. A special patient care protocol is also needed to manage the single implant over several days of treatment. The aim of this article is to describe our technique and rationale for prostate HDR monotherapy, and to put it in perspective, with educational intent.

Guidelines and recommendations on high-dose-rate brachytherapy for prostate cancer {#S0002}
==================================================================================

Clinical results for EBRT and HDR brachytherapy combination therapy have been accumulating, and they culminated in recommendations by the Groupe Européen de Curiethérapie/European Society for Radiotherapy and Oncology (GEC-ESTRO) \[[@CIT0010], [@CIT0011]\], and consensus guidelines by the American Brachytherapy Society (ABS) \[[@CIT0012]\]. The updated National Comprehensive Cancer Network (NCCN) guidelines in the USA state that HDR brachytherapy can be used in combination with EBRT (40-50 Gy) instead of LDR \[[@CIT0013]\]. As yet, however, no guidelines or recommendations have been established on HDR monotherapy for prostate cancer, therefore it should be undertaken in clinical trial settings.

Suitable patients for high-dose-rate monotherapy {#S0003}
================================================

Patient selection criteria for HDR prostate monotherapy are the subject of hot debate. Although our group\'s initial indication for HDR monotherapy was low- to high-risk prostate cancer \[[@CIT0005]\], subsequent researchers limited indications to low-risk or low-to-intermediate-risk patients \[[@CIT0014]--[@CIT0017]\]. As a result, some investigators maintained that HDR monotherapy was suitable only for low-risk or low-to-intermediate risk patients, and a combination of EBRT and HDR brachytherapy for intermediate- to high-risk patients, thus emulating the scheme for LDR brachytherapy. However, recently published reports with a relatively large number of patients revealed excellent biochemical control rates, even for intermediate- and high-risk patients \[[@CIT0018]--[@CIT0020]\], including our reports \[[@CIT0008], [@CIT0009]\]. Moreover, considering HDR monotherapy\'s capability to irradiate even extracapsular lesions, we think there is no reason to limit its indications to low-risk patients, and such indications now tend to be extended to high-risk patients. Our eligibility criteria are: 1) stage T1c-T3b, or T4 with only bladder neck invasion and N0M0 as established by clinical, biochemical, and imaging studies, including magnetic resonance imaging, computed tomography (CT), and bone scans; 2) suitable candidate for epidural anesthesia; and 3) informed consent. Patients are eligible for treatment independent of gland size, provided there is a sufficiently broad pelvic inlet and freedom from lower urinary tract symptoms. Patients are considered ineligible when they have had previous pelvic radiotherapy, surgery or transurethral resection of the prostate. Characteristics of our patients (who were accrued consecutively in the clinical trial setting and for whom informed consents were obtained) are shown in [Table 1](#T0001){ref-type="table"}, with information on accompanying hormone therapy.

###### 

Patient characteristics at Osaka University Hospital

  ----------------------------------------------------- ------------------- ------------------- ---------------------------------------------
  **Years**                                             1995-1996           1996-2005           2005-2010[\*](#TF0001){ref-type="table-fn"}
  **Dose-fractionation**                                48 Gy/8 fr/5 days   54 Gy/9 fr/5 days   45.5 Gy/7 fr/4 days
  **Number of patients**                                7                   112                 63
  **Age median (range)**                                67 (45-78)          68 (47-81)          69 (50-82)
  **T classification:**                                                                         
   **T1**                                               0                   28                  15
   **T2**                                               1                   34                  32
    **T3**                                              4                   46                  14
    **T4**                                              2                   4                   2
  **Gleason score:**                                                                            
    **≤ 6**                                             1                   50                  11
    **7**                                               1                   36                  34
    **≥ 8**                                             0                   26                  18
  **Pretreatment PSA (ng/ml):**                                                                 
    **\< 10.0**                                         1                   31                  26
    **10.0-20.0**                                       0                   31                  22
    **≥ 20.0**                                          6                   50                  15
    **Median (range)**                                  36.3 (7.0-150.0)    16.6 (3.8-233.0)    11.5 (3.9-378.5)
  **Risk group[\*\*](#TF0002){ref-type="table-fn"}:**                                           
    **Low**                                             0                   15                  --[\*\*\*](#TF0003){ref-type="table-fn"}
    **Intermediate**                                    1                   29                  34
    **High**                                            6                   68                  29
  **Hormone therapy**                                                                           
    **Low**                                             --                  9 (60%)             --
    **Median duration (range) (mo)**                    --                  16 (5-36)           --
    **Intermediate**                                    0 (0%)              19 (66%)            12 (35%)
    **Median duration (range) (mo)**                    --                  12 (3-156)          7 (1-24)
    **High**                                            5 (83%)             66 (97%)            25 (86%)
    **Median duration (range) (mo)**                    54 (45-180)         43 (2-188)          24 (4-94)
  **Follow-up (years)**                                                                         
    **Median (range)**                                  6.8 (3.3-17.4)      5.4 (1.3-11.4)      3.5 (1.1-6.0)
  ----------------------------------------------------- ------------------- ------------------- ---------------------------------------------

fr -- fractions, PSA -- prostate-specific antigen, mo -- months

Only patients until 2010 are reported, but this regimen is still ongoing.

Low (T1c-2a, GS ≤ 6 and PSA \< 10), intermediate (T2b-2c, GS -- 7 or PSA 10-20), high (T3-4, GS ≥ 8 or PSA ≥ 20).

I-125 seed permanent implant is indicated from 2005

Details of technique {#S0004}
====================

Applicator needle implant ([Fig. 1A](#F0001){ref-type="fig"}--[C](#F0001){ref-type="fig"}) {#S20005}
------------------------------------------------------------------------------------------

The implant technique has been previously described in detail by our group \[[@CIT0005]\]. Under epidural anesthesia, the patient is placed in a dorsal lithotomy position, with the perineal region sterilized. A balloon catheter is inserted into the bladder, with air-mixed gel placed within the prostatic urethra to enable visualization of the urethra on ultrasonography (US). Under real-time transrectal-US (TRUS) guidance, metallic applicator needles (Trocar Point Needles and Needle Stoppers^®^; Nucletron, an Elekta company, Sweden) are placed through the perineal skin, using our in-house template. The template is made of transparent acryl with 167 needle holes spaced at 5 mm intervals. The needles are placed along the line that encompasses the prostate at the largest cross-section on US, except for the rectal side where the needles are placed 2-3 mm inside the prostate contour. For T3 tumors, needles can be placed outside the prostate capsule and/or into the seminal vesicles. Inner needles are inserted at 1-cm intervals, to adequately cover the base and apex of the prostate, taking care in avoiding the urethra. The total number of needles inserted is usually around 15. The tips of the needles are placed 2 cm within the bladder pouch for the reason described in the following section. We recommend placing three or four metallic fiducial markers inside the prostate gland, as far apart as possible, with at least one at the base and another at the apex. They are useful for recognizing the relative shift between the prostate and the needles, as well as deformation of the prostate itself due to edema.

![A) Preparation for implant of applicator needles for HDR prostate brachytherapy. An in-house "see-through" template and its cover plate (center), an in-house metallic frame to hold and connect the template with an ultrasonography- probe stepper (right), applicator needles with stoppers (left), and their screws and screw drivers (upper). B) Needle implant under real-time transrectal-ultrasonography guidance. The patient is awake, under epidural anesthesia, in lithotomy position. Template holes had been superimposed on the ultrasonography monitor. C) Fixation of the template with elastic tape. Before taping, the template had been sutured to the perineal skin. Needle stoppers are sandwiched by the template and its cover plate, preventing needle displacement](JCB-6-22585-g001){#F0001}

Treatment planning ([Fig. 2A](#F0002){ref-type="fig"}, [B](#F0002){ref-type="fig"}) {#S20006}
-----------------------------------------------------------------------------------

After the implantation of the needles, CT data are acquired with the patient in the supine position (not in lithotomy). The CT slice thickness is 1.25 mm in helical mode. One hour before CT data acquisition and each irradiation fraction, the urinary balloon catheter is clamped in place to keep the urine within the bladder pouch, so that the cranial side of the bladder wall and the bowel are kept away from the irradiation volume.

![A) Three-dimensional reconstruction of the prostate and proximal seminal vesicles (pink), rectum (green), bladder (blue), urethra (cyan), and applicator needles and source dwell positions (red). Dwell positions were automatically selected by designating the area up to 7-mm outside the prostate or seminal vesicles. Note that some needles and dwell positions were entirely outside the prostate grand and/or partly in the seminal vesicles or in the bladder pouch. B) A dose distribution plot of transverse plane. Note that the urethral dose was \< 125% of the prescription dose, and the rectal dose \< 75%. Most parts of the rectum received \< 50% of the prescription dose, which would be difficult to achieve with EBRT (even with IMRT)](JCB-6-22585-g002){#F0002}

Computed tomography-based treatment planning is performed with the aid of Oncentra^®^ Brachy (Nucletron, an Elekta company, Sweden). The clinical target volume (CTV) includes the whole prostate gland with a 5-mm margin, except for the posterior (rectal) margin, which varies from 2 to 5 mm depending on the distance to the rectal wall. If extracapsular and/or seminal vesicle invasion are observed or strongly suspected, that area is included in the CTV and applicators are placed there. The planning target volume (PTV) is equal to the CTV, except in the cranial direction where it is increased by 1 cm, and includes the bladder base. The top 2 cm of the applicators are placed within the bladder pouch, so that the PTV includes a 1 cm margin in the cranial direction around the CTV. This margin is established, not only to avoid the cold area at the base of the prostate, but also to compensate for possible needle displacement in the caudal direction.

The dose distribution is created by geometric optimization (volume method) and manual modification. The following dose constraints are applied: the dose to the whole urethra should be 100-150% of the prescription dose, preferably \< 125%, and the dose to the whole rectal mucosa should be \< 100% of the prescription dose, preferably \< 80%. The PTV coverage requirements are D~90~ \> 100% (mandatory) and V~100~ \> 97% (preferable). The dose-volume constraint for the rectum is D~5cc~ \< 55%, which is drawn from our previous analysis, where D~5cc~ \< 27 Gy is a significant cut-off value for late rectal toxicity \[[@CIT0021]\]. The biologically effective dose (BED) of 27 Gy in 9 fractions in the previous analysis corresponded to 55% of the prescription dose in our ongoing dose-fractionation of 45.5 Gy in 7 fractions, assuming an α/β value for rectal mucosa of 3 Gy.

Patient management {#S20007}
------------------

The patient remains in bed for 4 days from Monday (implant day: Day 1) to Thursday (removal day: Day 4) under continuous epidural anesthesia, and undergoes irradiation twice daily with an interval of ≥ 6 hours. The treatment consists of 7 fractions of 6.5 Gy each (total 45.5 Gy). Anticoagulated patients are told to stop their drugs 1-2 weeks before the implant. To suppress defecation, the patients are given low-residue meals from Day 1 to Day 4. The patients should be given purgatives starting 4 days before the implant (magnesium oxide for 3 days and sennoside the night before) and a glycerin enema early in the morning of Day 1. The patients should also be encouraged to defecate before the implant. Prophylactic antibiotics are administered intravenously on Day 1 and Day 4, at the time of needle insertion and removal, and orally 3 times daily on Day 2 and Day 3. Pneumatic compression devices are attached to the patients' lower legs to prevent deep vein thrombosis from Day 1 through Day 4. To minimize bleeding (both from the perineum and intravesically), a coagulating agent (carbazochrome) is administered through an intravenous drip at the time of the implant and at the time of needle removal. Immediately after pulling the needles out, the physician should manually compress the prostate using both hands, one via the perineum and the other via the rectum (as in a digital examination), to stop the bleeding. In addition, pulling the balloon catheter, which has been replaced with a larger 3-way catheter for bladder irrigation, with the balloon inflated to its maximum, helps to stop bleeding from the bladder neck. For intravesical bleeding, bladder irrigation with cold saline is effective, and the continuous bladder irrigation technique is used to prevent clots from occluding the balloon catheter when intravesical bleeding is protracted.

Neoadjuvant and/or adjuvant hormone therapy {#S0008}
===========================================

The benefits of neoadjuvant and/or adjuvant hormone therapy are controversial. We assume that the therapy\'s additional benefit over RT alone would be smaller in the case of HDR brachytherapy than for EBRT (for example, classical 70-Gy EBRT), because BED of HDR brachytherapy is far higher than that of EBRT. However, some interaction between hormones and radiation may still occur, and the volume reduction effect may be associated with less toxicity. In our present protocol, patients with only one intermediate-risk feature are not given hormone therapy. The other intermediate-risk and all high-risk patients receive 6 to 12 months of neoadjuvant hormone therapy, but no adjuvant. If high-risk patients prefer to have long-term hormone therapy after being informed of its survival benefit in the case of EBRT, then adjuvant hormone therapy is allowed for up to 3 years total duration.

Patient outcomes {#S0009}
================

[Table 2](#T0002){ref-type="table"} lists clinical results of monotherapeutic HDR brachytherapy for prostate from the literature \[[@CIT0005]--[@CIT0007], [@CIT0015]--[@CIT0020], [@CIT0022]--[@CIT0027]\]. Only 10 institutions worldwide have reported clinical results for prostate HDR monotherapy. The longest median follow-up was 5.4 years, which was reported from our institution \[[@CIT0008]\], while the median follow-up of most of the studies was only 1-3 years.

###### 

Clinical results of HDR brachytherapy as monotherapy for prostate cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author \[ref.\]            HDR physical dose   BED (Gy)        EQD~2Gy~ (Gy)   No. of patients   Median follow-up (y)   Biochemical control (risk group)   Late toxicity ≥ Grade 2[\*](#TF0004){ref-type="table-fn"}                                                                                                                                              
  -------------------------- ------------------- --------------- --------------- ----------------- ---------------------- ---------------------------------- ----------------------------------------------------------- ----- --------------------------------------------------------------------- ------------------------------------------------------ ------- ---------
  Yoshioka \[[@CIT0009]\]    6 Gy                8 (1 implant)   48 Gy           240               144                    103                                86                                                          7     NA                                                                    NA                                                     NA      NA

  6 Gy                       9 (1 implant)       54 Gy           270             162               116                    97                                 112                                                         5.4   85% low-risk at 5 y93% intermediate-risk at 5 y79% high-risk at 5 y   7.1%                                                   7.1%    

  6.5 Gy                     7 (1 implant)       45.5 Gy         243             144               104                    86                                 63                                                          3.5   96% intermediate-risk at 3 y90% high-risk at 3 y                      6.3%                                                   1.6%    

  Demanes \[[@CIT0015]\]     7 Gy                6 (2 implant)   42 Gy           238               140                    102                                84                                                          298   5.2                                                                   97% low- and intermediate-risk at 5 y                  28.9%   \< 1.0%

  Martinez \[[@CIT0024]\]    9.5 Gy              4 (1 implant)   38 Gy           279               158                    119                                95                                                          248   4.8                                                                   88% low- and intermediate-risk at 5 y                  40.5%   2.0%

  Ghilezan \[[@CIT0017]\]    12 Gy               2 (1 implant)   24 Gy           216               120                    93                                 72                                                          50    1.4                                                                   NA                                                     25.5%   5.3%

  13.5 Gy                    2 (1 implant)       27 Gy           270             149               116                    89                                 44                                                                                                                                                                                                     

  Rogers \[[@CIT0018]\]      6.5 Gy              6 (2 implant)   39 Gy           208               124                    89                                 74                                                          284   2.7                                                                   94% intermediate-risk at 5 y                           7.7%    0.0%

  Zamboglou \[[@CIT0020]\]   9.5 Gy              4 (1 implant)   38 Gy           279               158                    119                                95                                                          141   4.4                                                                   95% low-risk at 5 y\                                   27.5%   2.6%
                                                                                                                                                                                                                                                                                                     93% intermediate-risk at 5 y\                                  
                                                                                                                                                                                                                                                                                                     93% high-risk at 5 y                                           

  9.5 Gy                     4 (2 implant)       38 Gy           279             158               119                    95                                 351                                                                                                                                                                                                    

  11.5 Gy                    3 (3 implant)       34.5 Gy         299             167               128                    100                                226                                                                                                                                                                                                    

  Hoskin \[[@CIT0019]\]      8.5 Gy              4 (1 implant)   34 Gy           227               130                    97                                 78                                                          30    4.5                                                                   99% intermediate-risk at 3 y\                          33.0%   13.0%
                                                                                                                                                                                                                                                                                                     91% high-risk at 3 y                                           

  9 Gy                       4 (1 implant)       36 Gy           252             144               108                    86                                 25                                                          5.0   40.0%                                                                 4.0%                                                           

  10.5 Gy                    3 (1 implant)       31.5 Gy         252             142               108                    85                                 109                                                         2.8   34.0%                                                                 7.0%                                                           

  Hoskin \[[@CIT0022]\]      13 Gy               2 (1 implant)   26 Gy           251               139                    108                                83                                                          115   0.2                                                                   NA                                                     5%      1%

  19 Gy                      1 (1 implant)       19 Gy           260             139               111                    84                                 24                                                          0.2   0%                                                                    0%                                                             

  20 Gy                      1 (1 implant)       20 Gy           287             153               123                    92                                 26                                                          0.2   9%                                                                    5%                                                             

  Ghadjar \[[@CIT0027]\]     9.5 Gy              4 (1 implant)   38 Gy           279               158                    119                                95                                                          36    3.0                                                                   100% low- and intermediate-risk at 3 y                 36.1%   5.6%

  Barkati \[[@CIT0016]\]     10 Gy               3 (1 implant)   30 Gy           230               130                    99                                 78                                                          19    3.3                                                                   88% low- and intermediate-risk at 3 y                  59.0%   5.1%

  10.5 Gy                    3 (1 implant)       31.5 Gy         252             142               108                    85                                 19                                                                                                                                                                                                     

  11 Gy                      3 (1 implant)       33 Gy           275             154               118                    92                                 19                                                                                                                                                                                                     

  11.5 Gy                    3 (1 implant)       34.5 Gy         299             167               128                    100                                22                                                                                                                                                                                                     

  Prada \[[@CIT0023]\]       19 Gy               1 (1 implant)   19 Gy           260               139                    111                                84                                                          40    1.6                                                                   100% low-risk at 2.7 y88% intermediate-risk at 2.7 y   0.0%    0.0%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HDR -- high-dose-rate; BED -- biologically effective dose; EQD~2Gy~ -- biologically equivalent dose in 2-Gy fractions; GU -- genitourinary; GI -- gastrointestinal; NA -- not applicable

Scored per event not per patient

The reported 5-year prostate-specific antigen (PSA) control rate for low-risk groups ranged from 85-97%, mostly \> 90%. For intermediate-risk groups, some authors reported a PSA control rate of 93-94%, and for high-risk groups, it was reported between 79 and 93%, mostly \> 80%. Although none of these studies have reported a follow-up period much beyond 5 years, the overall PSA control rates reported thus far have been excellent, which may be attributed to the high BED of \> 200 Gy discussed in the following section. The reported toxicity levels were generally acceptable ([Table 2](#T0002){ref-type="table"}).

Advantages/disadvantages of high-dose-rate monotherapy {#S0010}
======================================================

Advantages and disadvantages of prostate HDR monotherapy, compared to other treatment options, have been detailed in our review article published elsewhere \[[@CIT0028]\]. Below are the summaries, including (1-4) description of advantages with respect to radiation physics, (5) advantages with respect to radiobiology, and (6) disadvantages:Medical staff are never exposed to radiation and patients can stay in a regular ward since there is no need for a shielded room. Patients only need to go to an HDR unit room for irradiation for 30 minutes per fraction.Treatment planning is based on the CT images obtained after needle insertion, or on the TRUS images obtained at the time of needle insertion. The dwell positions of the stepping source are determined in terms of real anatomy. The dwell time for each dwell position is then calculated with an optimization algorithm.Unlike for EBRT, inter-/intra-fraction organ motion is not a problem with HDR brachytherapy. In the case of EBRT, several factors including daily set-up errors, retention of feces, gas, or urine, respiratory motion, or peristaltic motion result in discrepancies between the coordinates of the tumor and the radiation beam. With brachytherapy, these two coordinates are always concordant, because the tumor and the radioactive sources move in unison, so that PTV is normally identical to CTV. The overall treatment time for HDR monotherapy typically ranges from 1-4 days, significantly shorter than for EBRT.Unlike for LDR brachytherapy, HDR brachytherapy needles can be placed at the extracapsular lesion, and even into the seminal vesicles and/or into the bladder pouch. The cable-connected stepping source simply moves back and forth within the closed space without any risk of source migration or dropping out. Therefore, the indication for HDR monotherapy can potentially even be extended to T3a/b or some T4 tumors. The dwell time optimization makes a significant urethral dose reduction possible for HDR compared to that for LDR.Recent findings that the α/β value for prostate cancer is less than that for the surrounding late-responding normal tissue have made hypofractionation attractive, and HDR monotherapy can maximize this advantage of hypofractionation \[[@CIT0029]--[@CIT0033]\]. [Table 2](#T0002){ref-type="table"} lists dose-fractionations and associated BED and EQD~2Gy~ of HDR monotherapy from the literature. The BED for prostate cancer ranges from 208-299 Gy, with a median of 256 Gy. The values for EQD~2Gy~ range from 89-128 Gy with a median of 110 Gy, which may be impossible to administer with EBRT, even with IMRT. As for late toxicity, EQD~2Gy~ ranges from 72-110 Gy, with a median of 86 Gy, which can be considered the equivalent of the maximum dose of 86.4 Gy administered with the current IMRT. This means that, theoretically, hypofractionation with a large fraction size can enhance BED for prostate cancer without increasing BED for late-responding tissue.One of the possible drawbacks of HDR brachytherapy is the problem of applicator needle displacement during treatment ([Fig. 3](#F0003){ref-type="fig"}), which has been pointed out by some groups \[[@CIT0014], [@CIT0034]--[@CIT0041]\]. However, this problem does not arise if there is one fraction per implant \[[@CIT0020]--[@CIT0023]\]. Another drawback of HDR is the requirement of hospitalization and patients having to stay in bed during the treatment period. Further potential disadvantages of HDR are tumor edema and bleeding from needle insertion, causing changes in dosimetry from planning to treatment. In addition, if large doses are given to normal tissues (perhaps in less experienced centers), there is an increased risk of late toxicity, given the large dose per fraction.

![Treatment planning CT on the implant day (magenta) and on the last irradiation day (Day 4, gray), which were overlaid by matching positions of the metallic fiducial marker (VISICOIL^®^). Note that the geometry of needle fiducial template was kept constant, in contrary to the shift of pubic symphysis or sacral bone. However, the needles moved about 1 cm in the caudal direction, together with the template, which might be attributable to the perineal edema](JCB-6-22585-g003){#F0003}

Future directions {#S0011}
=================

High-dose-rate prostate monotherapy is still evolving and being developed, with ongoing research to determine optimal methodology and dose-fractionations. At our affiliated hospital, a new technique enabling more accurate implantation into seminal vesicles, and a new ambulatory technique for multi-fraction HDR brachytherapy have been developed \[[@CIT0042], [@CIT0043]\]. In view of its high degree of freedom, there may still be some room for improvement in the dwell time optimization algorithm \[[@CIT0044], [@CIT0045]\]. As for the problem of needle displacement, we are now testing daily CT scans to adjust needle positions or source dwell positions, by means of readjusting the relative locations of dwell positions to the gravity of the implanted fiducial markers. However, this method causes additional radiation exposure to the patient, which should be taken in to account as an intrinsic disadvantage.

Recent trends are moving towards a smaller number of fractions and shorter treatment. Many institutions previously used 4 fractions or more \[[@CIT0005], [@CIT0014], [@CIT0015], [@CIT0018]\]. However, researchers recently reported 3 fractions with 3 implants (1 fraction per implant) \[[@CIT0020]\], 2 fractions in a single day \[[@CIT0017]\], and even single fraction HDR monotherapy \[[@CIT0022], [@CIT0023]\]. Such an extremely hypofractionated regimen would maximize the therapeutic ratio, and at the same time avoid the HDR brachytherapy drawbacks of hospitalization and needle displacement during the treatment period. Finally, the authors would like to emphasize that HDR monotherapy has the largest potential to control prostate cancer without compromising toxicity, from the perspective of both radiation physics and radiobiology. Further clinical research is therefore clearly warranted.
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